With the ongoing emergence of SARS-CoV-2 variants, there is a need for standard approaches to characterize the risk of vaccine breakthrough. We aimed to estimate the association between variant and vaccination status in case-only surveillance data. Included cases were symptomatic adult laboratory-confirmed COVID-19 cases, with onset between January 2021 and April 2022, reported by five European countries (Estonia, Ireland, Luxembourg, Poland, and Slovakia) to The European Surveillance System. Associations between variant and vaccination status were estimated using conditional logistic regression, within strata of country and calendar date, and adjusting for age and sex. We included 80,143 cases including 20,244 Alpha (B.1.1.7), 152 Beta (B.1.351), 39,900 Delta (B.1.617.2), 361 Gamma (P.1), 10,014 Omicron BA.1, and 9,472 Omicron BA.2. Partially vaccinated cases were more likely than unvaccinated cases to be Beta than Alpha (adjusted odds ratio [aOR] 2.48, 95% CI 1.29-4.74), and Delta than Alpha (aOR 1.75, 1.31-2.34). Fully vaccinated cases were relative to unvaccinated cases more frequently Beta than Alpha (aOR 4.61, 1.89-11.21), Delta than Alpha (aOR 2.30, 1.55-3.39), and Omicron BA.1 than Delta (aOR 1.91, 1.60-2.28). We found signals of increased breakthrough infections for Delta and Beta relative to Alpha, and Omicron BA.1 relative to Delta.

Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023-6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7-98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.

Several SARS-CoV-2 variants that evolved during the COVID-19 pandemic have appeared to differ in severity, based on analyses of single-country datasets. With decreased testing and sequencing, international collaborative studies will become increasingly important for timely assessment of the severity of new variants. Therefore, a joint WHO Regional Office for Europe and ECDC working group was formed to produce and pilot a standardised study protocol to estimate relative case-severity of SARS-CoV-2 variants during periods when two variants were co-circulating. The study protocol and its associated statistical analysis code was applied by investigators in Denmark, England, Luxembourg, Norway, Portugal and Scotland to assess the severity of cases with the Omicron BA.1 virus variant relative to Delta. After pooling estimates using meta-analysis methods (random effects estimates), the risk of hospital admission (adjusted hazard ratio (aHR) = 0.41; 95% confidence interval (CI): 0.31−0.54), admission to intensive care unit (aHR = 0.12; 95% CI: 0.05−0.27) and death (aHR = 0.31; 95% CI: 0.28−0.35) was lower for Omicron BA.1 compared with Delta cases. The aHRs varied by age group and vaccination status. In conclusion, this study demonstrates the feasibility of conducting variant severity analyses in a multinational collaborative framework and adds evidence for the reduced severity of the Omicron BA.1 variant.

Several SARS-CoV-2 variants that evolved during the COVID-19 pandemic have appeared to differ in severity, based on analyses of single-country datasets. With decreased SARS-CoV-2 testing and sequencing, international collaborative studies will become increasingly important for timely assessment of the severity of newly emerged variants. The Joint WHO Regional Office for Europe and ECDC Infection Severity Working Group was formed to produce and pilot a standardised study protocol to estimate relative variant case-severity in settings with individual-level SARS-CoV-2 testing and COVID-19 outcome data during periods when two variants were co-circulating. To assess feasibility, the study protocol and its associated statistical analysis code was applied by local investigators in Denmark, England, Luxembourg, Norway, Portugal and Scotland to assess the case-severity of Omicron BA.1 relative to Delta cases. After pooling estimates using meta-analysis methods (random effects estimates), the risk of hospital admission (adjusted hazard ratio [aHR]=0.41, 95% CI 0.31-0.54), ICU admission (aHR=0.12, 95% CI 0.05-0.27), and death (aHR=0.31, 95% CI 0.28-0.35) was lower for Omicron BA.1 compared to Delta cases. The aHRs varied by age group and vaccination status. In conclusion, this study has demonstrated the feasibility of conducting variant severity analyses in a multinational collaborative framework. The results add further evidence for the reduced severity of the Omicron BA.1 variant.

Background Underlying conditions are risk factors for severe COVID-19 outcomes but evidence is limited about how risks differ with age. Aim We sought to estimate age-specific associations between underlying conditions and hospitalisation, death and in-hospital death among COVID-19 cases. Methods We analysed case-based COVID-19 data submitted to The European Surveillance System between 2 June and 13 December 2020 by nine European countries. Eleven underlying conditions among cases with only one condition and the number of underlying conditions among multimorbid cases were used as exposures. Adjusted odds ratios (aOR) were estimated using 39 different age-adjusted and age-interaction multivariable logistic regression models, with marginal means from the latter used to estimate probabilities of severe outcome for each condition–age group combination. Results Cancer, cardiac disorder, diabetes, immunodeficiency, kidney, liver and lung disease, neurological disorders and obesity were associated with elevated risk (aOR: 1.5–5.6) of hospitalisation and death, after controlling for age, sex, reporting period and country. As age increased, age-specific aOR were lower and predicted probabilities higher. However, for some conditions, predicted probabilities were at least as high in younger individuals with the condition as in older cases without it. In multimorbid patients, the aOR for severe disease increased with number of conditions for all outcomes and in all age groups. Conclusion While supporting age-based vaccine roll-out, our findings could inform a more nuanced, age- and condition-specific approach to vaccine prioritisation. This is relevant as countries consider vaccination of younger people, boosters and dosing intervals in response to vaccine escape variants.

Despite high COVID-19 vaccine coverage in the EU/EEA, there are increasing reports of SARS-CoV-2 infections and hospitalisations in vaccinated individuals. Using surveillance data from Estonia, Ireland, Luxembourg and Slovakia (January-November 2021), we estimated risk reduction of severe outcomes in vaccinated cases. Increasing age remains the most important driver of severity, and vaccination significantly reduces risk in all ages for hospitalisation (adjusted relative risk (aRR): 0.32; 95% confidence interval (CI): 0.26-0.39) and death (aRR: 0.20; 95% CI: 0.13-0.29).

Background: Underlying conditions have been found to be associated with severe COVID-19 outcomes, such as hospitalisation and death. This study aimed to estimate age-specific adjusted relative and absolute effects of individual underlying conditions on hospitalisation, death and in-hospital death among COVID-19 cases.Methods: We analysed case-based COVID-19 data submitted to The European Surveillance System (TESSy) between 2 June and 13 December 2020 by nine European countries. We individually assessed the association between 11 underlying conditions with hospitalisation, death and in-hospital death. Two additional categorical exposures were created: number of underlying conditions (1,2, ≥ 3) and the presence of any underlying condition (≥ 1). Adjusted ORs (aOR) for the association between each exposure condition and outcome were estimated using two multivariable logistic regression models: 1) an age-adjusted model and 2) an age-interaction model (exposure condition*age). All models were adjusted for sex, reporting period (June-September; October-December) and reporting country. From the age-interaction model we estimated the predicted probability of the three outcomes for each level of condition and age-group, marginalised over the levels of each covariable.Findings: After controlling for age, sex, reporting period and reporting country in the age-adjusted models, cases with cancer, cardiac disorder, diabetes, immune deficiency disorder, kidney disease, liver disease, lung disease, neurological disorders, obesity, any underlying condition or up to three or more conditions were between 1·5 and 5·6 times more likely to be hospitalised or die than cases with no underlying condition. Asthma was associated with increased overall risk of hospitalisation, not death. Age was an important modifier of these associations, with an age interaction present in the majority of models. For all outcomes, age-specific aOR in the age-interaction models tended to decrease with increasing age, whereas predicted probabilities of the outcome increased with age. For instance, individuals aged <20 years with any underlying condition were significantly more likely to be hospitalised (aOR: 5·16, 95%CI: 4·42 - 6·02) and die (aOR: 33·77, 95%CI: 12·57 - 90·75) compared to same-aged individuals without condition. The aOR fell to 1·77 (95%CI: 1·71 - 1·83) and 1·61 (95%CI: 1·55 - 1·68) respectively in individuals 80 years and older. Conversely, the predicted probabilities of hospitalisation and death among cases aged <20 years were 5·69% (95%CI: 4·97 - 6·51) and 0.15% (95%CI: 0·08 - 0·31), respectively, while they were 44·55% (95%CI: 43·68 - 45·43) and 16·31% (95%CI: 15·44 - 17·21), respectively for individuals aged 80 years and older. For some conditions, the probability of the outcome was at least as high in younger individuals with the condition as older cases without the condition.Interpretation: Several underlying conditions were found to have a significant independent effect on severe COVID-19 outcomes. Age is an important effect modifier in these associations. Interpretation of the results in this study is facilitated by considering together the estimates of relative (aOR) and absolute (predicted probabilities) effects that are presented. The presence of underlying conditions tended to have a larger relative effect in the young than the old, but the absolute probability of being hospitalised or dying increased with age. The finding that for some conditions, a younger person may have the same or even higher probability of severe outcome than an older person without it, has relevance for age and risk-factor based prioritisation of vaccination, particularly in the young.Funding Information: This study was funded through ECDC internal funding.Declaration of Interests: None to declare.

To guide evidence-based prevention of COVID-19 in children, we estimated risks of severe outcomes in 820,404 symptomatic paediatric cases reported by 10 EU Member States between August 2020 and October 2021. Case and hospitalisation rates rose as overall transmission increased but severe outcomes were rare: 9,611 (1.2%) were hospitalised, 640 (0.08%) required intensive care and 84 (0.01%) died. Despite increased individual risk (aOR; 95% CI for hospitalisation: 7.3; 3.3 - 16.2, ICU: 8.7; 6.2 - 12.3) in cases with comorbidities such as cancer, diabetes, cardiac or lung disease, most (83.7%) hospitalised children had no reported comorbidity. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The analysis is based on surveillance data reported to the European Surveillance System (TESSy) (www.ecdc.europa.eu and https://www.ecdc.europa.eu/en/covid-19/country-overviews) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

We estimated risks of severe outcomes in 820,404 symptomatic paediatric COVID-19 cases reported by 10 European Union countries between August 2020 and October 2021. Case and hospitalisation rates rose as transmission increased but severe outcomes were rare: 9,611 (1.2%) were hospitalised, 640 (0.08%) required intensive care and 84 (0.01%) died. Despite increased individual risk (adjusted odds ratio hospitalisation: 7.3; 95% confidence interval: 3.3–16.2; intensive care: 8.7; 6.2–12.3) in cases with comorbidities, most (83.7%) hospitalised children had no comorbidity.

Two Articles in The Lancet Infectious Diseases have called for enhanced COVID-19 testing capacity after demonstrating good diagnostic performance for RT-PCR testing of self-collected pooled nasal and throat swabs and nasal swabs1Tsang NNY So HC Ng KY Cowling BJ Leung GM Ip DKM Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.Lancet Infect Dis. 2021; (published online April 12.)https://doi.org/10.1016/S1473-3099(21)00146-8Summary Full Text Full Text PDF PubMed Scopus (169) Google Scholar and good sensitivity for rapid antigen diagnostic tests.2Boum Y Fai KN Nicolay B et al.Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study.Lancet Infect Dis. 2021; 21: 1089-1096Summary Full Text Full Text PDF PubMed Scopus (67) Google Scholar These important developments will help to control the pandemic, but the impact of changes in testing on surveillance data must be anticipated—ie, capacity to monitor the epidemiology of COVID-19. Since the start of the pandemic, testing and contact tracing have been the primary measures used to control the spread of SARS-CoV-2.3Cohen J Kupferschmidt K Countries test tactics in "war" against COVID-19.Science. 2020; 367: 1287-1288Crossref PubMed Scopus (248) Google Scholar Initially testing capacity was low, thus testing data were essential for interpretation of the COVID-19 case notification rate (ie, number of cases per 100 000 population) since the number of reported cases tended to only reflect the number of tests done. This remained true with increasing testing capacity, which enabled testing of mild or asymptomatic cases. The format of these indicators varied across countries, but the objectives were similar. For EU and European Economic Area (EEA) countries, the European Centre for Disease Prevention and Control (ECDC) calculates both testing rate (number of tests for SARS-CoV-2 infection per 100 000 population done in the previous week) and test positivity (percentage of positive tests among all tests for SARS-CoV-2 infection done in the previous week), which, among others, are also used by the European Council to coordinate the restriction of free movement in response to the COVID-19 pandemic.4Council of the European UnionCouncil Recommendation (EU) 2020/1475 of 13 October 2020 on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic (text with EEA relevance).https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32020H1475Date accessed: July 29, 2021Google Scholar The weekly testing rate at the level of EU and EEA countries has increased linearly since March, 2020, and exceeded 4000 tests per 100 000 population in May, 2021. This pattern continued despite fluctuations in notification rates. Although test positivity is easily calculated, the interpretation of such, and in particular, changes over time, can be challenging when both numerators and denominators vary for factors independent from the epidemiology (eg, case definition or testing strategies). For example, the EU case definition for COVID-19 that initially relied on the detection of SARS-CoV-2 nucleic acid (RT-PCR) has included detection of SARS-CoV-2 antigen in a clinical specimen since late 2020, which is less sensitive than RT-PCR. The introduction of target groups who are less likely to be symptomatic for testing, such as school-aged children, might also affect the test positivity. The emergence and rollout of new tests can impact testing indicators regardless of whether such indicators are listed in the laboratory criteria for case definitions. In the initial ECDC guidance on the use of rapid antigen tests for COVID-19 (before inclusion in the EU case definition), the inclusion of rapid antigen diagnostic tests was recommended when computing testing rates and test positivity.5ECDCOptions for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. Nov 19, 2020. European Centre for Disease Prevention and Control, Stockholm2020https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen-tests-for-COVID-19_0.pdfDate accessed: July 29, 2021Google Scholar However, the guidance also indicated that "positive confirmatory PCR or recurring rapid antigen diagnostic tests investigations in the same individual should not be included in these counts". The definition of frequent rapid antigen diagnostic tests might be challenging in settings in which asymptomatic individuals are required to be tested on a regular basis, such as schools. In countries in the EU and EEA, rapid antigen diagnostic tests are now widely available, although it is difficult to estimate their impact since information on laboratory methods is not available for 75% of cases reported to the ECDC. In Slovakia, approximately 55% of cases reported in 2021 were diagnosed by rapid antigen diagnostic tests. Now that self-tests are becoming more widely available, testing data might become even less reliable. Regarding the use of self-tests for COVID-19, the ECDC describes their possible impact on COVID-19 surveillance according to different scenarios considering the systematic use of confirmatory laboratory-based test, the reporting of self-test results, and the number of tests distributed.6ECDCConsiderations on the use of self-tests for COVID-19 in the EU/EEA. March 17, 2021. European Centre for Disease Prevention and Control, Stockholm2021https://www.ecdc.europa.eu/sites/default/files/documents/Considerations-for-the-use-of-self-tests-for-COVID-19-in-the-EU-EEA.pdfDate accessed: July 29, 2021Google Scholar In the absence of these components, there is a risk that testing indicators will be biased in an unpredictable way. Negative self-tests might not be reported and positive self-tests might not be confirmed by a laboratory-based test. Testing data are seldomly used in routine surveillance of infectious diseases. In most instances, the laboratory information collected is limited to the laboratory methods used to ascertain cases, but negative tests are not collected. Some countries such as the UK are now offering repeated testing to their entire population, inviting individuals to report their results online or by telephone.7UK Department of Health and Social CareTwice weekly rapid testing to be available to everyone in England.https://www.gov.uk/government/news/twice-weekly-rapid-testing-to-be-available-to-everyone-in-englandDate: April 5, 2021Date accessed: July 29, 2021Google Scholar Assuming that all results will be reported, these data could still be biased toward specific groups or locations, and sampling strategies would remain of importance for surveillance purposes.8Vandenberg O Martiny D Rochas O van Belkum A Kozlakidis Z Considerations for diagnostic COVID-19 tests.Nat Rev Microbiol. 2021; 19: 171-183Crossref PubMed Scopus (491) Google Scholar In response to the vaccine rollout and the continuous emergence of new variants, these strategies should be paired with sequencing strategies to ensure detection and monitoring of variants of concern.9ECDCGuidance for representative and targeted genomic SARS-CoV-2 monitoring. May 3, 2021. European Centre for Disease Prevention and Control, Stockholm2021https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-for-representative-targeted-genomic-SARS-CoV-2-monitoring.pdfDate accessed: July 29, 2021Google Scholar We declare no competing interests.

We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0–2.9; B.1.351: 3.6, 95% CI: 2.1–6.2; P.1: 2.6, 95% CI: 1.4–4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4–3.5; P.1: 2.2, 95% CI: 1.7–2.8).

Since December 2019, over 1.5 million SARS-CoV-2-related fatalities have been recorded in the World Health Organization European Region - 90.2% in people ≥ 60 years. We calculated lives saved in this age group by COVID-19 vaccination in 33 countries from December 2020 to November 2021, using weekly reported deaths and vaccination coverage. We estimated that vaccination averted 469,186 deaths (51% of 911,302 expected deaths; sensitivity range: 129,851–733,744; 23–62%). Impact by country ranged 6–93%, largest when implementation was early.

BackgroundAnnual seasonal influenza activity in the northern hemisphere causes a high burden of disease during the winter months, peaking in the first weeks of the year.AimWe describe the 2019/20 influenza season and the impact of the COVID-19 pandemic on sentinel surveillance in the World Health Organization (WHO) European Region.MethodsWe analysed weekly epidemiological and virological influenza data from sentinel primary care and hospital sources reported by countries, territories and areas (hereafter countries) in the European Region.ResultsWe observed co-circulation of influenza B/Victoria-lineage, A(H1)pdm09 and A(H3) viruses during the 2019/20 season, with different dominance patterns observed across the Region. A higher proportion of patients with influenza A virus infection than type B were observed. The influenza activity started in week 47/2019, and influenza positivity rate was ≥ 50% for 2 weeks (05-06/2020) rather than 5-8 weeks in the previous five seasons. In many countries a rapid reduction in sentinel reports and the highest influenza activity was observed in weeks 09-13/2020. Reporting was reduced from week 14/2020 across the Region coincident with the onset of widespread circulation of SARS-CoV-2.ConclusionsOverall, influenza type A viruses dominated; however, there were varying patterns across the Region, with dominance of B/Victoria-lineage viruses in a few countries. The COVID-19 pandemic contributed to an earlier end of the influenza season and reduced influenza virus circulation probably owing to restricted healthcare access and public health measures.

The European monitoring of excess mortality for public health action (EuroMOMO) network monitors weekly excess all- cause mortality in 27 European countries or subnational areas. During the first wave of the coronavirus disease (COVID-19) pandemic in Europe in spring 2020, several countries experienced extraordinarily high levels of excess mortality. Europe is currently seeing another upsurge in COVID-19 cases, and EuroMOMO is again witnessing a substantial excess all-cause mortality attributable to COVID-19.

Prioritisation of elderly people in COVID-19 vaccina-tion campaigns aimed at reducing severe outcomes in this group. Using EU/EEA surveillance and vaccination uptake, we estimated the risk ratio of case, hospitali-sation and death notifications in people 80 years and older compared with 25-59-year-olds. Highest impact was observed for full vaccination uptake 80% or higher with reductions in notification rates of cases up to 65% (IRR: 0.35; 95% CI: 0.13-0.99), hospitalisations up to 78% (IRR: 0.22; 95% CI: 0.13-0.37) and deaths up to 84% (IRR: 0.16; 95% CI: 0.13-0.20).

In the WHO European Region, COVID-19 surveillance was implemented 27 January 2020. We detail the first European cases. As at 21 February, nine European countries reported 47 cases. Among 38 cases studied, 21 were linked to two clusters in Germany and France, 14 were infected in China. Median case age was 42 years; 25 were male. Late detection of the clusters' index cases delayed isolation of further local cases. As at 5 March, there were 4,250 cases.

Two months after the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the possibility of established and widespread community transmission in the European Union and European Economic Area (EU/EEA) is becoming more likely. We provide scenarios for use in preparedness for a possible widespread epidemic. The EU/EEA is moving towards the ‘limited sustained transmission’ phase. We propose actions to prepare for potential mitigation phases and coordinate efforts to protect the health of citizens.

Decisions on school closures and on safe schooling during the COVID-19 pandemic should be evidence-based. We conducted a systematic literature review to assess child-to-child and child-to-adult SARS-CoV-2 transmission and to characterise the potential role of school closures on community transmission. 1337 peer-reviewed articles published through August 31, 2020 were screened; 22 were included in this review. The literature appraised provides sufficient evidence that children can both be infected by and transmit SARS-CoV-2 in community, household and school settings. Transmission by children was most frequently documented in household settings, while examples of children as index cases in school settings were rare. Included studies suggested that school closures may help to reduce SARS- CoV-2 transmission, but the societal, economic, and educational impacts of prolonged school closures must be considered. In-school mitigation measures, alongside continuous surveillance and assessment of emerging evidence, will promote the protection and educational attainment of students and support the educational workforce. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was financed by ECDC under direct service contract ECD.10660 with the University of Crete. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: n/a All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes This is a systematic review. All papers are referenced and searchable. ECDC data presented to complement the paper are available thorugh hyperlinks. <https://www.ecdc.europa.eu/en/covid-19/situation-updates> <https://www.ecdc.europa.eu/en/publications-data/download-data-response-measures-covid-19>

Background Back to school (BTS) asthma has been previously reported in children; however, its epidemiology and associated healthcare burden are unclear. We aimed to describe the timing and magnitude of BTS asthma using surveillance data from different health services in England.Methods Asthma morbidity data from emergency department attendances and general practitioner (GP) consultations between April 2012 and December 2016 were used from national syndromic surveillance systems in England. Age-specific and sex-specific rates and time series of asthma peaks relative to school term dates were described. The timing of a BTS excess period and adjusted rates of asthma relative to a baseline period were estimated using cumulative sum control chart plots and negative binomial regression.Results BTS asthma among children aged below 15 years was most pronounced at the start of the school year in September. This effect was not present among those aged 15 years and above. After controlling for sex and study year, the adjusted daily rate of childhood GP in-hours asthma consultations was 2.5–3 times higher in the BTS excess period, with a significantly higher effect among children aged 0–4 years. A distinct age-specific pattern of sex differences in asthma presentations was present, with a higher burden among males in children and among females aged over 15 years.ConclusionWe found evidence of a BTS asthma peak in children using surveillance data across a range of healthcare systems, supporting the need for further preventative work to reduce the impact of BTS asthma in children.

An outbreak of an uncommon emm type (emm66.0) of group A streptococcus (GAS) occurred in England and Wales between January 2016 and May 2017, involving 52 individuals who were homeless or injecting drugs users. In order to investigate the outbreak, epidemiological and network analysis were performed; moreover 55 isolates (32 outbreak, 5 non-outbreak and 13 historical - 2005-2015) were tested with whole genome sequencing (WGS), antimicrobial resistance determination, Bayesian evolutionary analysis (BEAST). Forty one isolates (including 32 outbreak strains) belonged to a single emm66.0 clade (average SNP difference 6.6; range 0-16 SNPs) separate from the other isolates and two strains previously considered part of the outbreak (SNP average: 5876; range 93-8417 SNPs). Antibiotic resistance was not detected in the outbreak clone. No common source of infection was identified. WGS confirmed expansion of an emm66.0 clone in a hard-to-reach population and enabled refinement of the initial case definition. (C) 2019 Published by Elsevier Ltd on behalf of The British Infection Association.